Ibio Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Ibio Inc in the fourth quarter 2026?
Ibio Inc recorded a cumulative net loss of $-33 million during 12 months ending in the fourth quarter 2026, resulting in a negative return on equity (ROE) of -56.44%.

Within the Major Pharmaceutical Preparations industry 179 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2026 from 3138 to 3367.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Equity Change	476.03 %	581.28 %	-30.22 %	215.64 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-33	-28	-25	-20	-18
Return On Equity (TTM)	-56.44 %	-67.61 %	-101.82 %	-77.62 %	-112.5 %
IBIO's Total Ranking	# 3367	# 3138	# 1272	# 2985	# 3069
Equity (TTM) in Millions	86	78	15	56	15
Seq. Equity Change	10.54 %	421.08 %	-73.45 %	276.61 %	30.74 %
Seq. Net Income Change	-	-	-	-	-

Back to IBIO Management Effectiveness >> IBIO's 5 Years Annual ROE >> Compare IBIO ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 180
Sector	# 430
Overall	# 3367

Return On Equity Statistics
High	Average	Low
-26.52 %	-127.57 %	-1004.65 %
(Jun 30 2021)		(Mar 31 2020)

News about Ibio inc Return on Equity ROE

The biotechnology landscape is on the cusp of a significant evolution, heralded by promising advancements f...

Revolutionizing Muscle Regeneration: iBio s Groundbreaking Advances in Anti-Myostatin Antibody Therapy The biotechnology landscape is on the cusp of a significant evolution, heralded by promising advancements from iBio, Inc. a pioneering bio-pharmaceutical company. iBio has released compelling new data on IBIO-600, its potentially best-in-class long-acting anti-myostatin antibody, and its first-in-class Activin E antibody, which collectively underscore the company’s commitment to advancing treatments for cardiometabolic diseases and obesity.In a recent announcement, iBio unveiled non-human primate pharmacokinetics data for IBIO-600, suggesting that this innovative candidate could exhibit a human half-life of up to 130 days. Such a prolonged half-life sets a new benchmark for anti-myostatin antibodies, hinting at a revolutionary shift in how muscular degeneration disorders, such as muscular dystrophy, could be managed in the future. Myostatin is a growth differentiation factor that suppresses muscle growth, making IBIO-600 s capability to extend half-life and promote muscle growth noteworthy.

iBio Expands Cardiometabolic and Obesity Research with Innovative Bispecific Antibody Program

: iBio Inc. has announced an expansion of its cardiometabolic and obesity program through the development of a novel bispecific antibody targeting Myostatin and Activin A, building upon the success of its existing anti-Myostatin program. This new therapy aims to promote weight loss, prevent muscle loss, and mitigate weight regain while potentially offering less frequent dosing compared to current obesity treatments available on the market. Obesity and related metabolic disorders represent significant health challenges worldwide, necessitating innovative therapeutic approaches. iBio Inc. leveraging its proprietary antibody development platform, has taken strides towards addressing these challenges by building upon its previous anti-Myostatin program. Recognizing the interventional potential in this area, iBio has now initiated a new program focusing on a bispecific antibody directed against Myostatin and Activin A.

IBIO Annual Return On Equity	(Jun 30 2026) 2026	(Jun 30 2025) 2025	(Jun 30 2024) 2024	(Jun 30 2023) 2023	(Jun 30 2022) 2022
Total Equity in Millions	86	15	21	15	63
Y / Y Equity Change	476.03 %	-30.22 %	38.64 %	-75.77 %	-41.54 %
Net Income in Millions	-33	-18	-25	-65	-50
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-38.55 %	-123.5 %	-116.8 %	-422.66 %	-79.24 %

Back to IBIO Management Effectiveness >> IBIO's 5 Years Annual ROE >> Compare IBIO ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IBIO's' Return on Equity at Yahoo Finance
IBIO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IBIO's Competitors
Subscribers only: Roe for Ibio Inc 's Suppliers
Subscribers only: Return On Equity for IBIO's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-08-29T06:23:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.